E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Paediatric patients with B-cell acute lymphoblastic leukaemia who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic SCT. |
|
E.1.1.1 | Medical condition in easily understood language |
Paediatric patients with a recurrent form of B-cell acute lymphoblastic leukaemia |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10063625 |
E.1.2 | Term | Acute lymphoblastic leukemia recurrent |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10063621 |
E.1.2 | Term | Acute lymphoblastic leukaemia recurrent |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
For Main Cohort and Cohort 1 : Evaluate the efficacy of CTL019 therapy from all manufacturing facilities as measured by overall remission rate (ORR) during the 3 months after CTL019 administration, which includes CR and CR with incomplete blood count recovery (CRi) as determined by IRC assessment; For Cohort 2 : To evaluate the feasibility and safety of CTL019 therapy in patients that relapsed < 6 months post allo-HSCT |
|
E.2.2 | Secondary objectives of the trial |
- Percentage of patients who achieve a best overall response of CR or CRi with a MRD negative bone marrow by central analysis using flow cytometry among all patients who receive CTL019 from all manufacturing facilities - Quality of response using MRD disease assessments before treatment and at day 28 +/- 4 days after treatment using central assessment by flow cytometry and before SCT by local assessment (flow or PCR) - Percentage of pts who achieve CR or CRi at Month 6 without SCT between CTL019 infusion and Month 6 response assessment - Percentage of pts who achieve CR or CRi and then proceed to SCT while in remission before Month 6 response assessment - Duration of remission, relapse-free survival, the event-free survival and overall survival - Safety of CTL019 therapy - Assess the efficacy, safety and in vivo cellular pharmacokinetics of patients infused with CTL019 manufactured by Fraunhofer Institute (except cohorts 1 and 2) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion Criteria: Relapsed or refractory pediatric B-cell ALL. a.2nd or greater Bone Marrow (BM) relapse OR. b.Any BM relapse after allogeneic stem cell transplantation (SCT) and must be ≥ 6 months from SCT at the time of CTL019 infusion OR c. Primary refractory as defined by not achieving a CR after 2 cycles of a standard chemotherapy regimen or chemorefractory as defined by not achieving a CR after 1 cycle of standard chemotherapy for relapsed leukemia OR d.Patients with Philadelphia chromosome positive (Ph+) ALL are eligible if they are intolerant to or have failed 2 lines of tyrosine kinase inhibitor therapy (TKI), or if TKI therapy is contraindicated OR. e.Ineligible for allogeneic SCT. 2.For relapsed patients, documentation of CD19 tumor expression in bone marrow or peripheral blood by flow cytometry within 3 months of study entry. 3.Adequate organ function defined as: a.Renal function defined as: A serum creatinine based on age/gender as follows: Maximum Serum Creatinine (mg/dL) - Age/Male/Female: 1 to < 2 years/0.6/0.6; 2 to < 6 years/0.8/0.8; 6 to < 10 years/1.0/1.0; 10 to < 13 years/1.2/1.2; 13 to < 16 years/1.5/ 1.4; ≥ 16 years/1.7/1.4. b.Alanine Aminotransferase (ALT) ≤ 5 times the upper limit of normal (ULN) for age. c.Bilirubin < 2.0 mg/dL. d.≤Grade1 dyspnea and pulse oxygenation > 91% on room air. e.Left Ventricular Shortening Fraction (LVSF) ≥ 28% confirmed by echocardiogram (ECHO), or Left Ventricular Ejection Fraction (LVEF) ≥ 45% confirmed by echocardiogram or Multiple Uptake Gated Acquisition (MUGA) within 7 days of screening. 4.Bone marrow with ≥ 5% lymphoblasts by morphologic assessment at screening. 5.Life expectancy > 12 weeks. 6.Age 3 at the time of screening to age 21 at the time of initial diagnosis 7.Karnofsky (age ≥ 16 years) or Lansky (age < 16 years) performance status ≥ 50 at screening. 8.Must have an leukapheresis product of non-mobilized cells received and accepted by the manufacturing site. Other protocol defined inclusion criteria may apply.
|
|
E.4 | Principal exclusion criteria |
1.Isolated extra-medullary disease relapse 2.Patients with concomitant genetic syndromes associated with bone marrow failure states: such as patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. Patients with Down Syndrome will not be excluded. 3.Patients with Burkitt's lymphoma/leukemia (i.e. patients with mature B-cell ALL, leukemia with B-cell [sIg positive and kappa or lambda restricted positivity] ALL, with FAB L3 morphology and /or a MYC translocation) 4.Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative intent and with no evidence of active disease XML File Identifier: hx8oujxBxuvLjDRpb/FBD+plMVg= Page 16/27 5.Treatment with any prior gene therapy product 6.Has had treatment with any prior anti-CD19/anti-CD3 therapy, or any other anti-CD19 therapy 7.Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening 8.Human Immunodeficiency Virus (HIV) positive test within 8 weeks of screening 9.Presence of grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD) 10.Active CNS involvement by malignancy, defined as CNS-3 per NCCN guidelines. Note: Patients with history of CNS disease that has been effectively treated will be eligible 11.Patient has an investigational medicinal product within the last 30 days prior to screening
Other protocol related exclusion criteria may apply. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall Remission Rate (ORR): Efficacy of CTL019 therapy - ORR includes Complete Remission (CR) and CR with incomplete blood count recovery (CRi) as determined by independent review committee (IRC) assessment. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary endpoint is assessed during the 3 months after CTL019 administration. |
|
E.5.2 | Secondary end point(s) |
- Percentage of patients with BOR of CR or CRi with MRD negative bone marrow by flow cytometry during the 3 months after CTL019 infusion among all patients who are infused with CTL019 from all manufacturing facilities - Percentage of patients who achieve CR or CRi at Month 6 without SCT between CTL019 infusion and Month 6 response assessment - Percentage of patients who achieve CR or CRi and proceed to SCT while in remission prior to Month 6 response assessment - Duration of remission - Relapse-free survival - Event-free survival - Overall survival - In vivo cellular PK profile (levels, persistence, trafficking) of CTL019 cells - Prevalence/incidence of immunogenicity to CTL019 - Safety: type, frequency and severity of adverse events and laboratory abnormalities
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The endpoints are assessed throughout the 60 months study duration. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 7 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
Japan |
United States |
Austria |
Belgium |
France |
Germany |
Italy |
Norway |
Spain |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study is defined as the last patients last visit (LPLV) which is the last patient's Month 60 evaluation or the time of premature withdrawal. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 6 |